流星花园2存储芯片涨的乱？逻辑脉络今天看！| 1111 张博划重点_我的网站
A | 11月11日，今日市场全天呈现冲高回落行情，其中受到AI硬件为首的科技股持续低迷，创业板指、科创50、深成指均跌超1%，沪指在银行等红利股护盘提振下表现相对偏强，仍收于4000点上方，沪深两市成交额不足2万亿。 CVS Health is planning to remove one type of a common decongestant from shelves after an advisory committee to the U.S. Food and Drug Administration said it was ineffective earlier this year.The products contain the oral formulation of phenylephrine (PE), which is found in several over-the-counter (OTC) medications.Although PE has been used as a decongestant for nearly a century, experts have been questioning its efficacy for years.The FDA Nonprescription Drugs Advisory Committee unanimously voted in September that PE did not improve nasal congestion any more than a placebo at the dosage given for OTC use.In response, CVS said it is removing products, in which PE is the only active ingredient from store shelves. This means products like Dayquil, which used a combination of active ingredients, will remain available for purchase."We are aware of the FDA Advisory Committee's position on oral phenylephrine (PE) and will follow direction from the FDA to ensure products we sell comply with all laws and regulations," CVS Health said in a statement. "We are removing certain oral cough and cold products that contain phenylephrine as the only active ingredient from CVS Pharmacy stores. Other oral cough and cold products will continue to be offered to meet consumer needs."CVS did not give specifies on brands that will be removed.The FDA told ABC News it has not yet determined whether it no longer considers PE to be a safe and effective medication and has not ordered the product to be removed from shelves. CVS's move is voluntary."The FDA has no further information to provide at this time regarding the timing of any decision the agency may make following the advisory committee meeting," the federal health agency said.The Consumer Healthcare Products Association told ABC News that the advisory committee's recommendation is a non-binding decision and not a change in regulation."FDA is currently in the process of reviewing the regulatory status of oral phenylephrine (PE) following September's advisory committee meeting," CHPA said in a statement. "Until FDA makes a determination on the committee's recommendation, oral PE remains a Category 1 OTC ingredient, which is generally recognized as safe and effective."Concerns were first raised about PE in 2007. Since then, evidence has accumulated showing that the drug offers little to no relief for nasal congestion.Experts believe this is because the body processes the drug before it reaches the nasal passages where it needs to work.It's unclear if other major retail pharmacy chains will follow in CVS's footsteps.Walgreens Boots Alliance would not disclose whether it was planning to remove products with PE from store shelves and said it would defer to the FDA."Walgreens follows FDA regulations. We are closely monitoring the situation and actively partnering with the Walgreens Office of Clinical Integrity and suppliers on appropriate next steps," a Walgreens spokesperson told ABC News.Other major pharmacy chains including Albertsons, Costco and Kroger did immediately reply to ABC News' request for comment. Walmart did not have an answer immediately available.ABC News' Sasha Pezenik and Sony Salzman contributed to this report.。结合今日微盘股指数续创历史新高，中证红利低波指数则录得日线七连涨，资金继续围绕小微盘+红利的“哑铃策略”展开布局。
B | 中国科学院半导体研究所宣布，近期研制出光电转换效率为27.2%的钙钛矿太阳能电池原型器件，受此消息提振，钙钛矿电池为首的光伏概念逆势大涨，中来股份、协鑫集成、拓日新能等多股涨停。而国家发改委、国家能源局发布关于促进新能源消纳和调控的指导意见，刺激储能概念卷土重来，海博思创、阿特斯、鹏辉能源等位居涨幅前列。 此外，据报道，头部多晶硅企业正筹划组建联合体，各方合计出资额可能在200亿至300亿元，旨在淘汰部分产能并清偿业内累积负债，或推动光伏行业"反内卷"进入新阶段。 Current article:http://www.bainangmieruopanglaomen.sbs/3tq9cg9/7onk.xlsx Published on:10:06:01 |
